Home
    Disclaimer
    ← Back to 1P-ETH-LAD
    1P-ETH-LAD molecular structure

    1P-ETH-LAD Stats & Data

    Psychedelic Research-chemical
    1pethlad
    NPS DataHub
    MW393.53
    FormulaC24H31N3O2
    IUPAC(6~{a}~{R},9~{R})-~{N},~{N},7-triethyl-4-propanoyl-6,6~{a},8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
    SMILESCCN(CC)C(=O)C1CN(CC)C2Cc3cn(C(=O)CC)c4cccc(C2=C1)c34
    InChIKeyMLOFCBXSOAYCIF-DYESRHJHSA-N
    2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT1A receptor agonist
    5-HT2C receptor agonist
    Other
    prodrug of ETH-LAD

    History & Culture

    1P-ETH-LAD emerged on the research chemical market in early 2016, with virtually no documented history of human usage prior to January of that year. The compound appeared alongside other novel lysergamide derivatives such as 1P-LSD and ETH-LAD, marketed primarily through online research chemical vendors as a legal alternative to LSD. As a relatively recent addition to the designer psychedelic landscape, 1P-ETH-LAD represents part of a broader wave of lysergamide analogs that entered commercial distribution during the mid-2010s. Its availability has been largely confined to the gray market research chemical trade, and comprehensive documentation of its use patterns and cultural context remains limited compared to more established psychedelics.

    Effect Profile

    Curated + 3 Reports
    Psychedelic 8.6

    Strong visuals, auditory effects, headspace, and body load

    Visual Intensity×3
    10
    Headspace Depth×3
    9
    Auditory Effects×1
    10
    Body Load / Somatic Effects×1
    8
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 1P-ETH-LAD The Drug Users Bible 1P-ETH-LAD

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    30 minutes - 1.5 hours
    30 minutes - 1.0 hours
    2-4 hours
    2-4 hours
    6-24 hours
    Total: 6-10 hours
    Sublingual
    15-45 minutes
    30 minutes - 1.0 hours
    2-4 hours
    2-4 hours
    6-24 hours
    Total: 6-10 hours

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    90% ●○○
    1P-LSD
    90% ●○○
    AL-LAD
    90% ●○○
    ETH-LAD
    90% ●○○
    ALD-52
    90% ●○○

    Experience Report Analysis

    Erowid
    3 Reports
    2015–2016 Date Range
    3 With Age Data
    1 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 3 experience reports (3 Erowid)

    3 Reports
    1 Effects Detected
    0 Positive
    0 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 0

    Adverse Effects 0

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Canada Schedule III (Precursor Control Regulations) Controlled as a Schedule III substance under the Precursor Control Regulations of the Controlled Drugs and Substances Act. This classification restricts production, distribution, and import.
    Germany Controlled (NpSG) Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Personal possession is prohibited but not subject to criminal penalties.
    Switzerland Controlled (Verzeichnis E) Classified as a controlled substance as a defined derivative of lysergic acid under Verzeichnis E point 263 of the narcotics scheduling. An exemption exists for legitimate scientific or industrial applications.
    Turkey Illegal Classified as a controlled drug. Possession, production, supply, and import are all prohibited under national drug legislation.
    United Kingdom Illegal (Psychoactive Substances Act) Prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and import are criminal offenses. Personal possession is not criminalized under this legislation, though intent to supply remains prosecutable.
    United States Unscheduled (Federal Analogue Act applies) Not explicitly scheduled at the federal level. However, when sold or possessed for human consumption, it may be prosecuted under the Federal Analogue Act as a substantially similar compound to scheduled lysergamides such as LSD.

    References

    Data Sources

    Cited References

    ← Back to 1P-ETH-LAD